Todd Campbell

Todd Campbell


Todd has been helping buy side portfolio managers as an independent researcher for over a decade. In 2003, Todd founded E.B. Capital Markets, LLC, a research firm providing action oriented ideas to professional investors. Todd has provided insight to a variety of publications, including SmartMoney, Barron's, and CNN/fn.

Recent articles


Abiomed's Heart Pump Can Improve Outcomes in Some Patients

New trial data supports the use of the company's Impella heart pumps in high-risk patients undergoing surgery to treat their coronary heart disease.


Why Selecta Biosciences Tumbled 34% Today

Disappointing phase 2 data casts doubt on SEL-212's future.


Here's Why Healthcare Stocks Are Falling This Week

Justice Ruth Bader Ginsburg's death jeopardizes Obamacare's future, and that puts healthcare companies' revenue at risk.


FDA Accepts Application for Bristol-Myers Squibb and bluebird bio's Multiple Myeloma CAR-T Therapy

The Food and Drug Administration's acceptance means it will issue a go/no-go decision on ide-cel in March 2021.


Roche Spends $451 Million to Acquire Inflazome's NLRP3 Program

The deal will provide the pharma giant with a unique new platform for tackling autoimmune diseases.


AstraZeneca's Lynparza Delivers Progression-Free Survival of Over 4 Years in Advanced Ovarian Cancer

The latest results from a long-term study of the drug enhance the case for its use.


Moderna Plans to Produce 20 Million Doses of Its COVID-19 Vaccine Candidate in 2020

The biotech is ramping up production ahead of the results from its late-stage clinical study of mRNA-1273.


New York Files Charges Against Johnson & Johnson Over Opioid Marketing

The healthcare giant is being charged with insurance fraud.


Bristol-Myers Squibb Cuts Deal, Delaying Threat to Top-Selling Revlimid

Bristol-Myers Squibb has come to terms on an agreement to delay entry of a generic version of its multiple myeloma drug, Revlimid.


Moderna Opens Its First Commercial Office in Europe

Its new operations in Switzerland will boost its EU presence as it aims to bring a COVID-19 vaccine to market worldwide.


Germany Awards $743 Million to BioNTech and CureVac for Coronavirus Vaccine Development

BioNTech and CureVac will use the new funding to advance COVID-19 research and development in Germany.


Merck Inks Multibillion-Dollar Deal With Seattle Genetics, Including Equity

Merck is acquiring $1 billion in Seattle Genetics shares as part of a wide-ranging collaboration agreement.


Pfizer Says It Could Know If Its COVID-19 Vaccine Candidate Works in October

The drugmaker's CEO said there was a more than 60% chance that they would know by the end of next month if BNT162b2 is effective.


Neurocrine Biosciences Officially Begins Marketing Its New Parkinson's Disease Drug

The much-anticipated launch of Ongentys has arrived.


Why Agenus Is Soaring 23.6% Today

Investor optimism is increasing ahead of an oral presentation at ESMO 2020.


Here's Why Fulgent Genetics Is Skyrocketing 16.7% Today

New York City will use the company's COVID-19 test in its public school system.


Why InMode Shares Are Skyrocketing 14.7% Today

The medical device maker announced a million-share repurchase program.


Why Fulgent Genetics Is Crashing Today

Abbott's announcement of a new 15-minute COVID-19 test threatens recent revenue growth.

Warren Buffett Just Bought These Stocks

Berkshire Hathaway's latest 13-F filing reveals interesting changes to his holdings.


Why Co-Diagnostics Skyrocketed 28.3% Today

The FDA has approved emergency use of its at-home COVID-19 test.